DOW JONES27,960.80-1031.61 -3.56%
S&P 5003,225.89-111.86 -3.35%
NASDAQ9,221.28-355.31 -3.71%

Cantor Fitzgerald Maintains Overweight on PTC Therapeutics, Raises Price Target to $81

Cantor Fitzgerald analyst Alethia Young maintains PTC Therapeutics (NASDAQ:PTCT) with a Overweight and raises the price target from $60 to $81.

Benzinga · 01/23/2020 16:05

Cantor Fitzgerald analyst Alethia Young maintains PTC Therapeutics (NASDAQ:PTCT) with a Overweight and raises the price target from $60 to $81.